Lipid metabolism and lung cancer
MM Salvador, MG de Cedrón, JM Rubio… - Critical reviews in …, 2017 - Elsevier
Lung cancer is currently one of the most serious health issues in developed and developing
countries. There are multiple available treatment options; however survival still remains very …
countries. There are multiple available treatment options; however survival still remains very …
[HTML][HTML] Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
J Xia, H Bai, B Yan, R Li, M Shao, L Xiong, B Han - Oncotarget, 2017 - ncbi.nlm.nih.gov
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are widely applied
to treat EGFR-mutant non-small cell lung cancer (NSCLC). BIM is a BH3 domain-containing …
to treat EGFR-mutant non-small cell lung cancer (NSCLC). BIM is a BH3 domain-containing …
Inhibiting IGF-1R attenuates cell proliferation and VEGF production in IGF-1R over-expressing EGFR mutant non-small cell lung cancer cells
CD Yeo, YA Kim, HY Lee, JW Kim, SH Lee… - Experimental lung …, 2017 - Taylor & Francis
Purpose: The aim of the present study was to demonstrate the role of insulin-like growth
factor-1 receptor (IGF-1R) tyrosine kinase inhibitors (TKIs) in IGF-1R expressed epidermal …
factor-1 receptor (IGF-1R) tyrosine kinase inhibitors (TKIs) in IGF-1R expressed epidermal …
[PDF][PDF] MiR-25 reduces PC-9/BB4 cell apoptosis sensitivity induced by gefitinib through downregulating BIM
Y Tang, G Xiao, Y Chen, Y Deng - Int J Clin Exp Med, 2017 - e-century.us
Bcl-2 interacting mediator of cell death (BIM) that mediated apoptosis was found to be
upregulated in drug resistant lung cancer cell line. It was showed that miR-25 significantly …
upregulated in drug resistant lung cancer cell line. It was showed that miR-25 significantly …